Meridian Life Science Announces USDA/APHIS EC 1774:2002 Approval for Its Viral Antigens Production Facility

CINCINNATI--(BUSINESS WIRE)--Meridian Life Science, Inc. (MLS) (NASDAQ:VIVO), today announced that its Viral Antigens production facility, located in Memphis, TN recently received USDA/APHIS EC 1774:2002 approval. This important regulatory approval, for one of the largest viral antigen production facilities in the US, is the latest demonstration of MLS’ commitment to serving our customers and improving our quality systems. This registration by the USDA/APHIS allows MLS to continue to manufacture and purify viral antigens for export to Europe and provide seamless and reliable outsourcing of large-scale, viral antigen production for all European customers.